SCHEMBL933787

SCHEMBL933787

O=C(Cl)C(Sc1ccc(Cl)cc1)c1ccc(Cl)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.53
CYP2C9 P11712 2/20 0.53
CYP2C19 P33261 2/20 0.53
MMP2 P08253 1/20 0.47
MMP8 P22894 1/20 0.47
MMP14 P50281 1/20 0.47
MMP1 P03956 1/20 0.43
TSHR P16473 1/20 0.42
BRD4 O60885 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40
CNR1 P21554 2/20 0.40
TRPA1 O75762 3/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
PLA2G1B P04054 1/20 0.38
THRB P10828 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL933825 0.92 CYP2C9 (0.46) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL933431 0.91 CYP2C9 (0.53) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL3521016 0.85 CYP2C9 (0.63) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL3518534 0.79 CYP2C9 (0.51) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL6788461 0.79 CYP2C9 (0.56) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL934473 0.78 LMNA (0.61) TSHRLMNASMN1; SMN2NPSR1L3MBTL1
SCHEMBL11563095 0.78 CYP2C9 (0.55) HSD17B10CYP2C9CYP2C19CNR1TRPA1
SCHEMBL11562132 0.78 CYP2C9 (0.59) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL28703755 0.78 CYP2C9 (0.59) HSD17B10CYP2C9CYP2C19MMP2MMP8
SCHEMBL933879 0.78 CYP2C9 (0.54) HSD17B10CYP2C9CYP2C19MMP2MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS ALLERGAN, INC. (US) 2012-04-12 US disclosed
WO-2011008475-A1 OPTIONALLY SUBSTITUTED 2-(ARYLMETHYL, ARYLOXY OR ARYLTHIO) -N- PYRIDIN-2 -YL-ARYL ACETAMIDE OR 2, 2-BIS (ARYL) -N-PYRIDIN-2-YL ACETAMIDE COMPOUNDS AS MEDICAMENTS FOR THE TREATMENT OF EYE DISEASES ALLERGAN, INC. (US) 2011-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088800-A1 2-(SUBSTITUTED) (ARYLMETHYL, ARYLOXY and ARYLTHIO))-N-(SUBSTITUTED PYRIDIN-2-YL)-2-(SUBSTITUTED ARYL) COMPOUNDS AS SUBTYPE-SELECTIVE MODULATORS OF SPHINGOSINE-1-PHOSPHATE-3 (S1P3) RECEPTORS S1PR3, S1PR5, S1PR1 HSD17B10 4088/4885CYP2C9 2965/4885CYP2C19 2153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.